CD274 and lung carcinoma: Graham et al demonstrated that activation of the PD‐1/PD‐L1 immune checkpoint confers tumour cell chemoresistance associated with increased metastasis;19 and Chen, et al also revealed that miR‐424(322) reverses chemoresistance via T cell immune response activation by blocking the PD‐L1 immune checkpoint.20 So we intended to prove that whether PD‐L1could lead chemoresistance in lung cancer and the effectiveness of PD‐L1 monoclonal antibody on immune escape and drug resistance induced by PD‐L1 increasing.